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Significance of this study
What is already known about this subject?
 ► Regular physical activity prevents development of 
diabetes mellitus.
What are the new findings?
 ► Physical activity—measured using a simple pe-
dometer—is an effective measure for objectively 
measuring physical activity in lifestyle studies and 
clinical practice.
 ► There is a highly, clinically significant dose-response 
relationship of pedometer steps with development of 
diabetes in a prediabetic population.
How might these results change the focus of 
research or clinical practice?
 ► Practitioners caring for those with prediabetes 
should ask patients to track physical activity with 
pedometer steps.
 ► To prevent the development of diabetes, at-risk pa-
tients should obtain up 10 000 steps per day.
AbStrAct
Objective Physical activity is related to clinical outcomes, 
even after adjusting for body mass, but is rarely assessed 
in randomized clinical trials.
Research design and methods We conducted an 
observational analysis of data from the Nateglinide 
and Valsartan in Impaired Glucose Tolerance Outcomes 
Research trial, in which a total of 9306 people from 40 
countries with impaired glucose tolerance and either 
cardiovascular disease or cardiovascular risk factors were 
randomized to receive nateglinide or placebo, in a 2-by-2 
factorial design with valsartan or placebo. All were asked 
to also participate in a detailed lifestyle modification 
programme and followed-up for a median of 6.4 years 
with progression to diabetes as a co-primary end point. 
Seven-day ambulatory activity was assessed at baseline 
using research-grade pedometers. We assessed whether 
the baseline amount of physical activity was related to 
subsequent development of diabetes in individuals with 
impaired glucose tolerance.
Results Pedometer data were obtained on 7118 
participants and 35.0% developed diabetes. In an 
unadjusted analysis each 2000-step increment in the 
average number of daily steps, up to 10 000, was 
associated with a 5.5% lower risk of progression to 
diabetes (HR 0.95, 95%CI 0.92 to 0.97), with >6% relative 
risk reduction after adjustment.
Conclusions Physical activity should be measured 
objectively in pharmacologic trials as it is a significant 
but underappreciated contributor to diabetes outcomes. It 
should be a regular part of clinical practice as well.
Physical activity is related to a plethora of clin-
ical outcomes, including all-cause mortality, 
cardiovascular disease (CVD), stroke, and 
diabetes mellitus. These relationships remain 
even after adjusting for body mass.1 2 Phys-
ical activity is an essential component of a 
number of lifestyle intervention studies for 
CVD3–6 and diabetes,7–10 but the effects 
of physical activity alone have rarely been 
studied prospectively in a clinical trial in 
subjects at high risk of diabetes or CVD, one 
exception being the LOOK AHEAD study of 
patients with diabetes.11 As intensive lifestyle 
intervention studies are expensive, burden-
some, and unlikely to be replicated it may be 
worthwhile to study relationships of physical 
activity in long-term clinical outcome trials of 
individuals with a high burden of risk where 
secondary observational analyses of these 
relationships may be more tenable. We have 
used data from the Nateglinide and Valsartan 
in Impaired Glucose Tolerance Outcomes 
Research (NAVIGATOR) Study12 for this 
purpose.
Physical activity was measured objectively 
using pedometers at baseline in all partici-
pants. Data for the association between phys-
ical activity and the incidence of CVD have 
been published previously.13 Here we use 
the baseline pedometer data to address the 
hypothesis that objectively measured base-
line physical activity, irrespective of study 
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arm assignment, would be related to the development of 
diabetes.
ReseaRCH design and meTHOds
naVigaTOR and study participants
NAVIGATOR ( ClinicalTrials. gov: NCT00097786) was a 
double-blind, randomized, placebo-controlled clinical 
trial with a 2-by-2 factorial design. It evaluated whether 
valsartan or nateglinide, in addition to lifestyle modifi-
cation, could reduce the risk of diabetes and cardiovas-
cular events in people with impaired glucose tolerance 
who either had CVD or risk factors for CVD.14 15 Details of 
the trial, including the protocol, results, and design, have 
been published.12 14 15 A total of 9306 participants from 
40 countries participated in the trial for a median of 5.0 
years for the diabetes outcome.
Lifestyle modification intervention and identification of 
incident diabetes
All participants participated in the lifestyle program 
designed to achieve and maintain a 5% weight loss; 
reduce dietary saturated and total fats; and increase phys-
ical activity to 150 min/week. Study staff provided infor-
mation at each visit in the first year consisting of written 
materials and videos with reinforcement via telephone 
contacts. The co-primary outcome of incident diabetes 
was defined as the development of a fasting plasma 
glucose ≥7.0 mmol/L and/or 2-hour glucose (measured 
2 hours after oral glucose load) ≥200 mg/dL (≥11.1 
mmol/L), confirmed on oral glucose tolerance test 
performed within 12 weeks. Diagnoses of diabetes made 
outside of the study were adjudicated by an independent 
committee blinded to treatment allocation.
Physical activity measures
Habitual ambulatory activity was assessed objectively using 
research-grade pedometers (Accusplit AE120, San Jose, 
California, USA) in all NAVIGATOR Study centers. The 
pedometers measured purposeful steps taken through a 
horizontal, spring-suspended lever arm moving vertically 
with each step, activating an electric circuit, and regis-
tering a step. Two weeks after the initial baseline, clinical 
measurements were taken, participants were fitted with a 
pedometer and instructed to wear it during waking hours 
for seven consecutive days. Participants were given a log 
book and instructed to write down their daily step counts 
at the end of each day and then return the log book to 
the study team.
statistical analysis
Continuous variables are reported as medians (25th, 
75th percentiles); categorical variables are reported by 
proportions. Patient characteristics were compared using 
the Pearson's χ2 test or Fisher's exact test for categorical 
variables and with the Kruskal-Wallis test for continuous 
variables. Unadjusted and adjusted Cox proportional 
hazards regression models were used to assess the asso-
ciations of physical activity (pedometer steps) with the 
clinical outcomes. Covariate adjustment was imple-
mented in three stages. First, we report an unadjusted 
model. Second, we adjusted for age, sex, and region, 
avoiding other patient characteristics that might be on 
the causal pathway between exercise and outcome. Third, 
a fully adjusted model added all variables significantly 
contributing to the prediction of diabetes in a baseline 
model in the original study.16 These factors or variables 
are listed in the footnotes of the respective tables.
Using a backward selection technique, the adjustment 
model was a priori selected as only those factors which 
at baseline were associated with the incidence of type 
2 diabetes in this study.
We tested the proportional hazards assumption and 
linearity assumption for pedometer steps. As the linearity 
assumption was not satisfied we tested two spline pieces 
in our models. Since the second piece was distant from 
being significant, the pedometer data were truncated 
at 10 000 steps per day. In order to preserve important 
information on non-missing covariates and improve our 
multivariable models, pedometer data for the 23% of 
missing baseline data were handled by multiple imputa-
tion. The final models used five imputed data sets, and 
the results were combined using valid statistical methods 
that account for imputation variation. In order to investi-
gate whether imputation affected the strength of results, 
the analysis was repeated for the subset of 7118 partici-
pants with complete data. For all outcomes, two parallel 
analyses were performed: (1) All patients with pedom-
eter measurements (n=7118). (2) Five imputed data sets. 
The point estimates of the HRs were very similar for 
these analyses. Since the results from the complete case 
and imputed (n=9308) data sets were similar, we report 
here only the results from the imputed data. Note, the 
linearity assumption was not satisfied for pedometer 
steps; two spline pieces were tested in the model and the 
final model only included the first piece, which is equiv-
alent to truncating the pedometer steps at 10 000 steps 
per day.
A two-sided P value<0.05 was considered statisti-
cally significant for main effects. A P value <0.1 was 
considered statistically significant for interactions. Statis-
tical analyses were done using SAS V.9.2 (SAS Institute, 
Cary, North Carolina, USA).
ResuLTs
Baseline pedometer data were obtained on 7118 of the 
9306 NAVIGATOR participants. Mean (SD) daily steps by 
quarters at baseline were 1831 (1151), 4652 (659), 7096 
(800), and 11 240 (2344) steps per day. table 1 reports 
biochemical, anthropometric, and behavioral variables 
of study participants by quartile of baseline pedometer 
steps, particularly those included in the adjustment 
models as indicated by notations and in the footnotes.
Table 2 reports the HRs, CIs, and P values for the 
development of diabetes according to the three models, 
with figure 1 showing the unadjusted Kaplan-Meier plot. 
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Table 1  Baseline characteristics by quartiles of pedometer steps
Characteristic
Quarter 1
(N=2326)
Quarter 2
(N=2327)
Quarter 3
(N=2327)
Quarter 4
(N=2326) P values
Average daily pedometer steps at month 0.5, 
median (25th, 75th) 2006 (859, 2859) 4659 (4085, 5216) 7093 (6382, 7754) 10 5699 (9447, 12299) <0.0001
Age at screening, median (25th, 75th), years*,† 65 (59, 71) 64 (59, 69) 63 (58, 68) 62 (57, 66) <0.0001
Female, no. (%)*,† 1259 (54.1) 1224 (52.6) 1197 (51.4) 1031 (44.3) <0.0001
Pooled race group: original, no. (%)*,† <0.0001
  White 1996 (85.8) 1985 (85.3) 1943 (83.5) 1810 (77.8)
  Black 87 (3.7) 58 (2.5) 55 (2.4) 36 (1.5)
  Asian 76 (3.3) 116 (5.0) 145 (6.2) 276 (11.9)
  Other 167 (7.2) 168 (7.2) 184 (7.9) 204 (8.8)
Current smoker, no. (%)* 319 (13.7) 246 (10.6) 237 (10.2) 223 (9.6) <0.0001
Region, no. (%)*,† <0.0001
  Asia 58 (2.5) 96 (4.1) 134 (5.8) 264 (11.3)
  Europe 1149 (49.4) 1253 (53.8) 1279 (55.0) 1228 (52.8)
  Latin America 311 (13.4) 332 (14.3) 362 (15.6) 401 (17.2)
  North America 716 (30.8) 575 (24.7) 483 (20.8) 372 (16.0)
  Other 92 (4.0) 71 (3.1) 69 (3.0) 61 (2.6)
BMI, median (25th, 75th), kg/m2† 31.2 (27.7, 35.4) 30.2 (27.1, 33.9) 29.3 (26.7, 32.7) 28.4 (26.0, 31.6) <0.0001
Height, median (25th, 75th), cm 165 (158, 173) 165 (158, 172) 165 (158, 172) 165 (159, 172) 0.3250
Weight, median (25th, 75th), kg 85.7 (74.3, 99.0) 83.0 (72.5, 94.5) 80.9 (71.0, 91.3) 79.0 (69.1, 89.1) <0.0001
Waist circumference, median (25th, 75th), cm* 104 (96, 113) 101 (93, 110) 99 (91, 107) 98 (89, 105) <0.0001
Systolic BP, median (25th, 75th), mm Hg† 140 (129, 151) 140 (129, 150) 139 (127, 150) 139 (128, 150) 0.0002
Diastolic BP, median (25th, 75th), mm Hg 82 (76, 90) 82 (76, 90) 81 (76, 90) 82 (76, 90) 0.5490
Pulse rate, median (25th, 75th), bpm* 70.0 (64.0, 78.0) 70.0 (62.0, 78.0) 70.0 (63.0, 76.0) 70.0 (62.0, 76.0) 0.0142
Family history of diabetes, no. (%) 868 (37.3) 896 (38.5) 882 (37.9) 901 (38.7) 0.7525
Cardiovascular disease, no. (%) 807 (34.7) 743 (31.9) 706 (30.3) 677 (29.1) 0.0003
Atrial fibrillation/flutter, no. (%)* 112 (4.8) 99 (4.3) 79 (3.4) 66 (2.8) 0.0021
Pulmonary embolism/deep vein no. (%)* 42 (1.8) 34 (1.5) 33 (1.4) 20 (0.9) 0.0499
COPD/emphysema/chronic bronchitis, no. (%)* 149 (6.4) 118 (5.1) 104 (4.5) 80 (3.4) <0.0001
Hypertension, no. (%) 1812 (77.9) 1827 (78.5) 1763 (75.8) 1814 (78.0) 0.1151
Congestive heart failure, no. (%)* 112 (4.8) 80 (3.4) 81 (3.5) 58 (2.5) 0.0003
Left ventricular hypertrophy, no. (%) 72 (3.1) 62 (2.7) 64 (2.8) 70 (3.0) 0.7886
Cerebrovascular disease no. (%) 220 (9.5) 186 (8.0) 181 (7.8) 149 (6.4) 0.0019
Coronary heart disease, no. (%)*,† 716 (30.8) 669 (28.7) 635 (27.3) 606 (26.1) 0.0026
PAD composite, no. (%)* 99 (4.3) 90 (3.9) 69 (3.0) 51 (2.2) 0.0003
ECG interpretation, no. (%)* 0.0004
  Normal 1053 (45.3) 1095 (47.1) 1178 (50.6) 1199 (51.5)
  Clinically insignificant abnormality 884 (38.0) 865 (37.2) 793 (34.1) 784 (33.7)
  Clinically significant abnormality 389 (16.7) 367 (15.8) 356 (15.3) 343 (14.7)
Family history of premature CHD, no. (%) 386 (16.6) 395 (17.0) 411 (17.7) 352 (15.1) 0.1245
Fasting glucose, median (25th, 75th), mmol/L† 6.1 (5.7, 6.4) 6.1 (5.7, 6.4) 6.1 (5.7, 6.4) 6.1 (5.7, 6.5) 0.1925
2-hour glucose, median (25th, 75th), mmol/L† 9.1 (8.4, 9.9) 9.1 (8.4, 9.9) 9.0 (8.3, 9.9) 9.0 (8.3, 9.9) 0.0665
HbA1c, median (25th, 75th), %† 5.9 (5.6, 6.2) 5.8 (5.6, 6.1) 5.8 (5.5, 6.1) 5.8 (5.5, 6.0) <0.0001
Hemoglobin, median (25th, 75th), g/L*,† 146 (137, 155) 147 (138, 155) 146 (138, 155) 148 (139, 156) 0.0052
LDL cholesterol, median (25th, 75th), mmol/L*,† 3.18 (2.53, 3.80) 3.21 (2.60, 3.92) 3.26 (2.62, 3.95) 3.23 (2.63, 3.93) 0.0012
HDL cholesterol, median (25th, 75th), mmol/L† 1.22 (1.03, 1.46) 1.24 (1.04, 1.47) 1.24 (1.03, 1.50) 1.25 (1.04, 1.48) 0.0227
Non-HDL cholesterol, median (25th, 75th), 
mmol/L 4.04 (3.35, 4.75) 4.06 (3.41, ,4.86) 4.11 (3.46, 4.83) 4.04 (3.36, 4.83) 0.0152
Non-HDL cholesterol/total cholesterol ratio, 
median (25th, 75th) 0.77 (0.72, 0.81) 0.77 (0.72, 0.81) 0.77 (0.72, 0.81) 0.76 (0.71, 0.81) 0.1095
Total cholesterol, median (25th, 75th), mmol/L 5.30 (4.62, 6.00) 5.39 (4.68, 6.14) 5.40 (4.73, 6.16) 5.35 (4.66, 6.12) 0.0048
Continued
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Characteristic
Quarter 1
(N=2326)
Quarter 2
(N=2327)
Quarter 3
(N=2327)
Quarter 4
(N=2326) P values
Triglycerides, median (25th, 75th), mmol/L 1.8 (1.3, 2.4) 1.7 (1.3, 2.4) 1.7 (1.2, 2.4) 1.6 (1.2, 2.2) <0.0001
eGFR, median (25th, 75th), mL/min/1.73 m2 77.7 (65.4, 88.3) 77.8 (67.2, 89.1) 80.1 (69.5, 92.0) 82.6 (71.3, 94.3) <0.0001
Albumin/creatinine ratio, median (25th, 75th), 
mg/mmol 0.90 (0.55, 2.00) 0.84 (0.51, 1.80) 0.79 (0.50, 1.56) 0.77 (0.50, 1.67) 0.0028
Log of albumin/creatinine ratio, median (25th, 
75th), mg/mmol* −0.11 (-0.60, 0.69) −0.17 (-0.67, 0.59) −0.24 (-0.69, 0.44) −0.26 (-0.69, 0.51) <0.0001
Sodium, median (25th, 75th), mmol/L* 142 (141, 144) 142.0 (141.0, 144.0) 142.0 (141.0, 144.0) 142.0 (141.0, 144.0) 0.1052
Potassium, median (25th, 75th), mmol/L 4.3 (4.1, 4.6) 4.3 (4.1, 4.6) 4.3 (4.1, 4.6) 4.3 (4.1, 4.6) 0.3125
White blood cell, median (25th, 75th), 109/L 6.9 (5.8, 8.1) 6.8 (5.8, 8.0) 6.6 (5.7, 7.7) 6.5 (5.5, 7.6) <0.0001
Platelet, median (25th, 75th), 109/L† 254 (215, 299) 254 (213, 297) 252 (212, 297) 247 (207, 289) <0.0001
Renal dysfunction, no. (%) 44 (1.9) 20 (0.9) 16 (0.7) 10 (0.4) <0.0001
α blocker, no. (%) 153 (6.6) 153 (6.6) 135 (5.8) 136 (5.8) 0.5188
ACE inhibitor, no. (%) 197 (8.5) 178 (7.6) 157 (6.7) 144 (6.2) 0.0152
Antihypertensives, no. (%) 1778 (76.4) 1720 (73.9) 1664 (71.5) 1654 (71.1) <0.0001
ARB, no. (%) 11 (0.5) 10 (0.4) 6 (0.3) 3 (0.1) 0.1396
Aspirin, no. (%) 892 (38.3) 892 (38.3) 833 (35.8) 808 (34.7) 0.0185
β blocker, no. (%) 975 (41.9) 923 (39.7) 911 (39.1) 857 (36.8) 0.0054
Calcium channel blocker, no. (%) 784 (33.7) 765 (32.9) 694 (29.8) 769 (33.1) 0.0226
Diuretic, no. (%) 840 (36.1) 769 (33.0) 714 (30.7) 637 (27.4) <0.0001
Lipid lowering agent, no. (%) 907 (39.0) 923 (39.7) 896 (38.5) 851 (36.6) 0.1606
*In death, myocardial infarction, or stroke model.
†In diabetes mellitus baseline model.
ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; bpm, beats per minute; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; 
eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PAD, peripheral arterial disease.
Table 1  Continued
Table 2  Clinical outcomes by every 2000 pedometer steps per day (up to 10 000). Development of diabetes (Using five 
imputed data sets: N=9306, events=3254; C-index=0.527)
Models Label HR 95% CI χ2 P values
Unadjusted model Average daily pedometer steps per 2000 greater up to 
10 000
0.95 0.92 to 0.97 21.74 <0.0001
Adjusted model 1* Average daily pedometer steps per 2000 greater up to 
10 000
0.95 0.92 to 0.96 24.99 <0.0001
Adjusted model 2† Average daily pedometer steps per 2000 greater up to 
10 000
0.96 0.94 to 0.99 8.529 0.0042
*Adjusted for age, sex, and region.
†Adjusted for age; sex; region; race; body mass index; systolic blood pressure; family history of diabetes; composite of history of myocardial 
infarction (MI), unstable angina, or coronary revascularization; fasting glucose; 2-hour glucose on oral glucose tolerance test; hemoglobin 
A1C; low-density lipoprotein cholesterol; high-density lipoprotein cholesterol; platelet count; and hemoglobin concentration.
Cardiovascular and Metabolic Risk
During the study period, 35.0% (3254 of 9306) of partici-
pants developed diabetes. On average, each 2000 greater 
number of daily steps, up to 10 000, was associated with a 
5.5% lower risk of progression to diabetes (HR 0.95, 95% 
CI 0.92 to 0.97; P<0.0001) in the unadjusted analysis. The 
observations remained similar and statistically signifi-
cant when analyzed adjusting for age, sex, and region of 
origin (HR 0.95, 95% CI 0.92 to 0.96; P<0.0001), or when 
analyzed in the fully adjusted model (HR 0.96, 95% CI 
0.94 to 0.99; P=0.0042).
To address the potential for effect modification by 
gender, we tested for an interaction of gender and 
pedometer steps on outcome for this manuscript and, the 
P value was not statistically significant (data not shown).
disCussiOn
In this post hoc observational analysis of NAVIGATOR 
data, a 24% lower risk of diabetes was seen in those with 
impaired glucose tolerance and either CVD or cardiovas-
cular risk factors who had a baseline physical activity level 
of 10 000 steps/day compared with 2000 steps/day. In 
this cohort, change in ambulatory activity is associated 
with a reduced risk of cardiovascular outcomes.13 The 
findings from this study suggest that a reduced risk of 
type 2 diabetes may have been one mechanism contrib-
uting to this previously observed association.
The data linking regular physical activity with diabetes 
outcomes derive largely from large population-based 
 o
n
 24 February 2019 by guest. Protected by copyright.
http://drc.bmj.com/
BM
J O
pen Diab Res Care: first published as 10.1136/bmjdrc-2018-000523 on 19 July 2018. Downloaded from 
5BMJ Open Diab Res Care 2018;6:e000523. doi:10.1136/bmjdrc-2018-000523
Figure 1  Kaplan-Meier survival curves for the development of diabetes by quartiles of baseline pedometer steps. 
Probabilities of diabetes mellitus (DM) curves were compared using log-rank test (P<0.0001). Individuals at risk at each visit of 
follow-up were: 9306 (V0), 8230 (V1), 7524 (V2), 7178 (V3), 6582 (V4), 6229 (V5), 5572 (V6), 4876 (V7), 4275 (V8), 2931 (V9), and 
510 (V10).
Cardiovascular and Metabolic Risk
cohort studies and were reviewed and summarized in 
the Surgeon General’s Report on Physical Activity and 
Health1 and more recently in the Physical Activity Guide-
lines Advisory Committee Report2 serving as the basis of 
the 2008 Physical Activity Guidelines for Americans. In 
the past, most of these data were derived from self-report 
or survey tools that, while carefully derived and validated, 
suffered from a number of inherent confounders and 
limitations associated with such approaches. Recently, 
the physical activity epidemiology field has begun to 
rely on objective measures of physical activity, derived 
from pedometers or accelerometers, to investigate 
the associations between regular physical activity and 
cardiometabolic health.17 A meta-analysis of 17 studies 
of physical activity in individuals with diabetes shows that 
each 1 metabolic equivalent hour/day of greater physical 
activity (roughly equivalent to 20 min of walking or 2000 
steps) incrementally was associated with a 9.5% (5.0%–
13.8%)%) and 7.9% (4.3%–11.4%)%) lower risk of 
all-cause mortality and CVD risk.18 The data in this report 
from the NAVIGATOR Study support and confirm these 
associations for CVD outcomes in the novel setting of a 
rigorously conducted and assessed prospective clinical 
pharmaceutical trial in a large international population 
broadly representative of those targeted with diabetes 
and CVD prevention programs in routine clinical care. 
In the setting of an enriched clinical trial, individuals 
carry a greater absolute risk for events (in this case 
diabetes) than would be available in a generalized popu-
lation-based setting. In addition, the clinical trial setting 
carries the advantage of regular, close follow-up; stan-
dardized collection and adjudication of events; in this 
case and, most important, repeat and regular follow-up 
of clinical laboratory testing (eg, oral glucose tolerance 
testing) to diagnose diabetes mellitus.
The results of the analysis presented here support the 
independent effects of objectively measured physical 
activity on metabolic outcomes and the notion that all 
pharmaceutical studies of incident or established diabetes 
should consider the independent influence of physical 
activity levels on the trial outcomes, as is done for other 
relevant covariates. As physical activity was measured 
by self-report in the major prevention trials, it has not 
been possible to use these studies to precisely define 
the importance of physical activity in the prevention of 
type 2 diabetes. This study aims to assess the association 
between physical activity and diabetes progression using 
an objective measurement tool (a pedometer) with a 
universally understood metric (steps/day) in the context 
of an international cohort.
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This study has several strengths. Physical activity was 
objectively measured using a readily available simple 
instrument—the pedometer. The collection of a plethora 
of clinical data on the study subjects, the uniformity of 
the study population, and the prospective nature of the 
data collection provide the opportunity to control for 
a broad range of clinical characteristics strengthening 
confidence in the strength of the observed associations.
There are several limitations. The study was not 
designed to test the association between physical activity 
and diabetes outcomes, opening the possibility for 
unmeasured confounding. That is, subjects were not 
randomized on the basis of baseline physical activity; 
nor were they randomized to changes in physical activity. 
Further, less active individuals tend to be the least healthy 
—this is true of any population. We have attempted to 
account for this by adjustment for a comprehensive list 
of factors found to be associated with the incidence of 
type 2 diabetes in the fully adjusted model. However, 
we acknowledge that confounding by unmeasured 
confounders—or residual confounding from measured 
factors—remain possibilities. Still, the dose-response 
relation between habitual physical activity level and the 
clinical outcomes provides confidence regarding the 
fidelity of the observations. Further, since the hypothesis 
being tested was not a primary study objective, there were 
missing data on objective measures of physical activity; 
however, we believe that this limitation was effectively 
addressed with the imputation and sensitivity analyses. 
Also, due to the nature of the study tool, we could not 
address whether intensity of physical activity was related 
to outcome. That would require accelerometry or 
another similar tool to address this important question 
in this setting.
It also is important to make the distinction between 
physical activity and cardiorespiratory fitness; this study 
assessed the former, not the latter. There is a strong asso-
ciation between cardiorespiratory fitness and cardiomet-
abolic outcomes as well as all-cause mortality.19–21 Further, 
there is an association between habitual physical activity 
and cardiorespiratory fitness; however, as genetics play 
a strong role in the determination of this relation and 
in cardiorespiratory fitness itself, the relation is far from 
perfect. The study reported here only applies to the rela-
tion of baseline habitual physical activity and incident 
diabetes mellitus. There was no measure of fitness in this 
study.
The LOOK AHEAD investigators did not observe a 
significant effect of a combined lifestyle intervention 
including physical activity on cardiovascular outcomes 
in older individuals with type 2 diabetes mellitus.11 
Several differences in the design of that study and the 
one reported herein may explain the different observa-
tions. Probably the most important difference is in the 
study populations. LOOK AHEAD studied those with 
established diabetes, often established for some lengthy 
period, and NAVIGATOR was designed to study events 
in those at high risk of developing diabetes, but without 
frank disease at onset. It may be that the state of the vascu-
lature in those with established disease is not amenable 
to modification by lifestyle interventions, including phys-
ical activity. This distinction would be worth testing in a 
prospective study. That being said, as they are supported 
by observations in a recent publication from our group 
showing that even modest changes in physical activity 
during the study are reflected in better cardiovascular 
outcomes, we are confident in the observations reported 
here.13
COnCLusiOns
In this secondary analysis of a clinical trial where partic-
ipants were already at high risk of cardiovascular events 
and progression to diabetes, each greater 2000-step per 
day difference in baseline activity (roughly equivalent to 
20 min of moderate-paced walking per day) was associated 
with a 5.5% lower risk of developing diabetes over the 
course of the study, even when studied in a fully adjusted 
model containing other pertinent clinical elements. 
This observation demonstrates the utility of objective 
measures of physical activity in clinical trials and suggests 
that assessments of lifestyle in pharmacologic outcomes 
trials should be part of regular clinical trials and clinical 
practice in general.
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